SinoMab BioScience Limited (HKG:3681)

Market Cap	1.57B -43.4%
Revenue (ttm)	n/a
Net Income	-116.83M
EPS	-0.10
Shares Out	1.39B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	815,100
Open	1.130
Previous Close	1.130
Day's Range	1.120 - 1.250
52-Week Range	0.990 - 3.760
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About SinoMab BioScience

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-class anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 95
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3681

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error